Timothy Noyes
Vorstandsvorsitzender bei AEROVATE THERAPEUTICS, INC.
Aktive Positionen von Timothy Noyes
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AEROVATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2021 | - |
Vorstandsvorsitzender | 01.02.2021 | - |
Karriereverlauf von Timothy Noyes
Ehemalige bekannte Positionen von Timothy Noyes
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Arcuate Therapeutics, Inc.
Arcuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcuate Therapeutics, Inc. engages in the pharmaceutical industry. The company is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | 01.10.2019 | 01.02.2021 |
Vorstandsvorsitzender | 01.10.2019 | 01.02.2021 | |
Präsident | 01.10.2019 | 01.02.2021 | |
PROTARA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2006 | 01.01.2020 |
Vorstandsvorsitzender | 01.01.2006 | 01.01.2020 | |
Präsident | 01.01.2006 | 01.01.2020 | |
PROTARA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2006 | 01.09.2019 |
Vorstandsvorsitzender | 01.04.2006 | 01.11.2017 | |
Präsident | 01.04.2006 | 01.11.2017 | |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Geschäftsführer | - | 03.09.2008 |
Trine Pharmaceuticals, Inc.
Trine Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA. | Geschäftsführer | 01.08.2002 | 01.03.2006 |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Präsident | 01.09.1996 | 01.01.2002 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2001 | 01.01.2002 |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Timothy Noyes
Harvard College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 13 |
Operativ
Director/Board Member | 5 |
Chief Executive Officer | 4 |
President | 4 |
Sektoral
Health Technology | 11 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
PROTARA THERAPEUTICS, INC. | Health Technology |
AEROVATE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Trine Pharmaceuticals, Inc.
Trine Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trine Pharmaceuticals, Inc. develops and markets pharmaceutical products. It develops drugs which are used in the areas of renal, gastrointestinal and metabolic diseases. The company is headquartered in Waltham, MA. | Health Technology |
Iconix Biosciences, Inc.
Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | Health Technology |
Proteon Therapeutics, Inc.
Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals, Inc. BiotechnologyHealth Technology GelTex Pharmaceuticals, Inc. was developed non-absorbed, polymer-based pharmaceuticals that selectively bind and eliminate target substances from the intestinal tract. The company is a subsidiary of Geltex Corp. GelTex Pharmaceuticals was founded by Henry E Blair & James B Tananbaum in 1991 and was located in Waltham, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Arcuate Therapeutics, Inc.
Arcuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcuate Therapeutics, Inc. engages in the pharmaceutical industry. The company is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Timothy Noyes
- Erfahrung